NCT00021736已完成2 期
Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 540
- 试验地点
- 1
研究概览
简要总结
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
详细描述
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center, by percentage of classic CNV vessels: [predominantly classic (>50%) vs. minimally classic (1-49%) vs. purely occult (0%)], and according to whether, or not, they have received prior PDT with Visudyne (no more than once). All patients will be re-randomized after 54 weeks of treatment to either, continue or discontinue therapy for further 48 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of either gender, aged 50 years or above, diagnosed with subfoveal CNV secondary to AMD and with best corrected visual acuity of 20/40 to 20/320 in the absence of subfoveal atrophy or scarring in the study eye, and better or equal to 20/800 in the fellow eye, may be enrolled. Clinically significant concomitant diseases will be excluded.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Macular DegenerationNCT00637377Bayer1,240
已完成
2 期
Evaluation of RC28-E Injection in Diabetic Macular EdemaDiabetic Macular EdemaNCT04782115RemeGen Co., Ltd.156
已完成
2 期
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerSquamous Cell Carcinoma of the BladderStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder CancerAdenocarcinoma of the BladderDistal Urethral CancerProximal Urethral CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerNCT00407485National Cancer Institute (NCI)22
已完成
2 期
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersNeuroendocrine CarcinomaNCT01121939SCRI Development Innovations, LLC43
已完成
2 期
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerMetastatic Renal Cell CarcinomaNCT00357760National Cancer Institute (NCI)94